Quantcast
Last updated on April 19, 2014 at 9:20 EDT

Latest Ipilimumab Stories

2012-03-08 13:43:48

Study describes a rare case of the abscopal effect in a melanoma patient Research published today in the New England Journal of Medicine by scientists at the Ludwig Institute for Cancer Research (LICR) and Memorial Sloan-Kettering Cancer Center (MSKCC) showed that combining targeted radiation therapy with immunotherapy (ipilimumab), fostered a strong immune response and a favorable clinical outcome in a patient with melanoma, the most dangerous form of skin cancer. The size of both the...

117736034
2011-08-22 13:01:29

The first new skin cancer treatment since the 1970s has now gone on sale in Britain, according to a Monday morning article by Telegraph Health Correspondent Martin Beckford. The drug is known as ipilimumab, and according to the American Cancer Society, it is "a type of immunotherapy known as a monoclonal antibody," which is definite as "a man-made version of an immune system protein that fits like a lock and key with a certain protein in the body." "Ipilimumab is designed to seek out...

1bba6e6ced73cce47ad966bbae6ea6d3
2011-08-18 10:55:00

The US Food and Drug Administration (FDA) on Wednesday approved the cancer treatment drug Zelboraf, used to treat patients with late-stage or unresectable melanoma, the most dangerous form of skin cancer. The drug specifically treats patients with melanoma whose tumors express a gene mutation called BRAF V600E. The drug has not been tested on patients whose melanoma tests negative for the mutation by an approved FDA diagnostic. Zelboraf is being approved with a test called the cobas 4800...

2011-06-06 12:56:15

A duo of drugs, each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase 1 clinical trial led by Dana-Farber Cancer Institute investigators. The findings (abstract 8511), will be presented in an oral session at the annual meeting of the American Society of Clinical Oncology on Saturday, June 4, 3 p.m. CT, Arie Crown Theater, McCormick Place. The drugs --...

c7d7d7588c7904c027290ba4e1c2ec19
2011-06-06 12:35:00

A new study found that people with advanced melanoma who were treated with Bristol-Myers Squibb Co.'s Yervoy plus chemotherapy lived an average of two months longer than people who got chemotherapy alone. The study is the first to show that combining chemotherapy and an immune-system treatment is safe and effective for patients with advanced melanoma. It is also the second major trial to show Yervoy (ipilimumab), a new type of immunotherapy drug, can improve survival in patients with the...

2011-04-28 00:15:44

Like brainy bookworms unprepared for the rough and tumble of post-graduation life, white blood cells trained by scientists to attack tumors tend to fade away quickly when injected into cancer patients. Dana-Farber Cancer Institute scientists, however, have developed a technique that can cause such cells to survive in patients' bloodstreams for well over a year, in some cases, without the need of other, highly toxic treatments, a new study shows. In a paper published in the Apr. 27 issue of...

f2d1d174e9ad266b2a3df2720b6258b21
2011-03-26 08:45:00

A drug from Bristol-Myers Squibb Co. shown to help prolong the lives of people suffering from advanced skin cancer has been approved by the US Food and Drug Administration on Friday.The injectable drug, called Yervoy (ipilimumab), is used for late-stage melanoma. Bristol-Myers Squibb aims to use the drug to harness the body's immune system to target and attack melanoma tumors."Yervoy is the first therapy approved by the FDA to clearly demonstrate that patients with metastatic melanoma live...

2011-03-25 19:04:34

First drug approved in more than a decade The U.S. Food and Drug Administration today approved the use of ipilimumab for the treatment of previously treated metastatic melanoma. It is the first drug approved for metastatic, or advanced, melanoma is more than a decade. "Ipilimumab is the first in a new class of drugs that has been shown to offer a survival benefit for metastatic melanoma, which is often a fatal disease, and hopefully, this will lead to the development of related treatments for...

2011-03-25 11:23:00

Melanoma patients lived longer with treatment SILVER SPRING, Md., March 25, 2011 /PRNewswire-USNewswire/ --The U.S. Food and Drug Administration today approved Yervoy (ipilimumab) to treat patients with late-stage (metastatic) melanoma, the most dangerous type of skin cancer. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO) Melanoma is the leading cause of death from skin disease. An estimated 68,130 new cases of melanoma were diagnosed in the United States during 2010 and...

2010-12-09 17:22:28

Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung...